For the past two decades, Paul Michaels has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics, and Gilead, and more.
Paul has also provided financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead (formerly Nexstar Pharmaceuticals). Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market in addition to other corporate responsibilities that included overall evaluation of corporate asset values. Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder, he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
As an adult-onset Type 1 diabetic, Paul knows firsthand how a patient can struggle to get the right diagnosis and treatment. Only 40,000 adults a year are diagnosed with Type 1 diabetes. Paul is actively involved in the Juvenile Diabetes Research Foundation (JDRF), a global organization funding research for Type 1 diabetes.
Dr. Barry Ginsberg is an accomplished professional who advises executives across industries, bringing expertise in strategy and performance in the pharmaceuticals and medical products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care, and patient education. Combined with an expansive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the team.
Dr. Ginsberg’s community service participation included the Flying Samaritans and One Sight. He recently retired after practicing over 35 years in the medical field. He participated in four Externships including the Feinbloom Low Vision Center in Philadelphia, focusing on Age Related Macular Degeneration (AMD) and the Goldschleger Eye Institute in Tel Hashomer Hospital in Israel, focusing on diseases of the eye including Glaucoma.
A communications and marketing leader, Pam Bisikirski guided the brand development of multiple healthcare optical centers including America’s Best Contacts & Eyeglasses and Eyeglass World while working at National Vision, Inc, (EYE) a $1.7 billion company. During her 20 year tenure at National Vision she managed the public relations for the organization as well as multi million dollar partnerships and endorsement programs.
Pam has also led communications as a consultant in the healthcare and retail spaces and is experienced with both start ups and rapidly expanding companies. Pam sat on the Board of Directors of Prevent Blindness Georgia for 6 years, the maximum allowed by the charitable foundation that is dedicated to preserving sight. She remains active in the organization.
Michael Grace has 30 years of executive and technical experience in both research and development of protein therapeutics and peptides within the biotechnology industry at Schering-Plough, Bristol Myers Squibb, NPS Pharma and Advaxis Inc. He has contributed to or personally led the development to commercial approval of 9 drugs by FDA and EMA including PEG-Intron™, Orencia™, Nulojix™, Yervoy™, Gattex™ and Natpara™. His experience encompasses all aspects of drug development from discovery, process development, analytical development, quality control and regulatory. He is well-published within his field of expertise and has presented world-wide on several aspects of protein analytics, characterization, and process and product development.
Ronald Bordens is an accomplished executive scientist with over 40 years of successful experience in biotechnology and pharmaceutical industries for companies focused on research and development. He possesses a unique skill set including but not limited to people leadership, scientific expertise, and quality assurance and control. His pharmaceutical industry experience includes drug discovery, drug development and research technology with a focus on bioanalytical research, biomarkers, and leadership development from his 26-year career at Schering-Plough Research.
I. Richard Garr, Esq., was a Director, and Neuralstem’s Chief Executive Officer and President from 1996 through February of 2016. Additionally, as a co-founder and General Counsel at Neuralstem, Mr. Garr had responsibility and oversight for all operations of a world-leading regenerative medicine company including worldwide business development, joint ventures, and licensing. and created the Stem cell industry’s first development agreements for Korea, Indonesia, Singapore, Malaysia, and Vietnam. In 2016. Mr. Garr became a full-time advocate for patient’s rights to access experimental treatments in development both in the U.S. and Europe. In 2018, he founded Access Hope CRO, the only CRO dedicated exclusively to facilitating safe, ethical, and legal expanded patient access to potentially life-saving investigational treatments under the Trickett Wendler, Frank Mongiello, Jordan McLinn and Mathew Bellina Right to Try Act of 2018. Mr. Garr is a graduate of Drew University (1976) and the Columbus School of Law, The Catholic University of America (1979). Furthermore, he was a founder and is a current Board member of the First Star Foundation, a children’s charity focused on abused children’s issues; a founder of The Starlight Foundation Mid-Atlantic chapter, which focuses on helping seriously ill children; and a past Honorary Chairman of the Brain Tumor Society.